@drteplinsky: Let’s review the OASIS-4 trial results presented at ASCO and published in the New England Journal of Medicine. This study evaluates elinzanetant for vasomotor symptoms (hot flashes and night sweats) in patients with breast cancer (stage 0-3) on endocrine therapy (either tamoxifen or an aromatase inhibitor). Elinzanetant blocks two brain receptors, NK1 and NK3, which are involved in regulating body temperature. It is a non hormonal option. It is in same class of meds as Veozah but this is the first study study results we have of looking at this med in patients w breast cancer. Participants were randomized into 2 groups: elinzanetant or placebo x12 weeks and then elinzanetant. 316 participants were in the elinzanetant group and 158 in the placebo- elinzanetant group. The dose of elinzanetant is 120 mg daily. At baseline, the average daily frequency of moderate to severe vasomotor symptoms was 11.4 episodes in the elinzanetant group. At 4 weeks: the mean change from baseline in the average daily frequency of moderate-to-severe vasomotor symptoms was -6.5 episodes in elinzanetant group and -3.0 episodes in placebo group (there’s a placebo effect!). At 12 weeks: the mean change from baseline in the average daily frequency of moderate-to-severe vasomotor symptoms was -7.8 episodes in elinzanetant group and -4.2 episodes in placebo group. Elinzanetant also resulted in greater improvement in sleep disturbances and menopause related quality of life. In exploratory analyses, more than 70% of the participants treated with elinzanetant had a reduction in symptoms of at least 50% at 12 weeks Headaches, joint pain and nausea were seen in both groups (but in no more than ~10-12% of participants). Somnolence, fatigue, and diarrhea were reported more frequently with elinzanetant than with placebo during weeks 1 through 12. No deaths occurred during the trial. Majority of the participants in this study were White which limits the applicability of the results and while patients at risk of breast cancer were allowed, only 1 patient on study was taking endocrine therapy to reduce the risk of breast cancer. The tentative deadline for the FDA to make a decision is end of July 2025 so we will see if this becomes an option! Let me know your questions! What has been your experience with hot flashes? #elinzanetant #breastcancer #hotflashes #menopause #menopausetok #nightsweats #oncologist

Eleonora Teplinsky, MD

Open In TikTok:

Region: US

Tuesday 03 June 2025 22:00:34 GMT